Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short‐lived WT1‐specific immune responses

Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short‐lived WT1‐specific immune responses

B Uttenthal, I Martinez‐Davila, A Ivey… - British journal of …, 2014 - Wiley Online Library

... D-Ala-εAhx-Cys-OH (Alexander et al, 1994)] peptides were synthesized to GMP grade by Bachem
UK Ltd. ... of preparation at two separate sites, to avoid competitive binding of HLA-A*0201 by the
WT1 peptides. ... Three dose levels were used, comprising 0·3, 0·6 or 1·0 mg peptide. ...

Peptide synthesis, peptide modification and peptide library synthesis, please contact:

Eva He

eva@pepmic.com

Pepmic Co., Ltd

www.pepmic.com